MYL7
Myosin regulatory light chain 2, atrial isoform
As of the edition of 20 October 2026, MYL7 (myosin regulatory light chain 2, atrial isoform, UniProt Q01449) has 2 drugs tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q01449
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Bones, joints and muscles; Lungs and airways; Nervous system
- Registered trials of its drugs
- 24
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Omecamtiv mecarbil | Active | Phase 3 | none listed |
| Danicamtiv | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |